Opinion

Video

The Impact of Targeted Gene Therapy and Nadofaragene Firadenovec on BCG-Unresponsive NMIBC

Author(s):

A panelist discusses how targeted gene therapy, particularly nadofaragene firadenovec, represents a paradigm shift in BCG-unresponsive NMIBC treatment.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      1. How has the introduction of targeted gene therapy changed the way you approach managing BCG-unresponsive NMIBC?
        1. What are the broader implications of using gene therapy to treat BCG-unresponsive NMIBC, and how does nadofaragene firadenovec fit into this landscape overall?
      Related Content
      © 2025 MJH Life Sciences

      All rights reserved.